Analysts at Evercore ISI began coverage on shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) in a report issued on Wednesday, Marketbeat Ratings reports. The firm set an “in-line” rating and a $83.00 price target on the biotechnology company’s stock. Evercore ISI’s price target points to a potential upside of 5.12% from the stock’s previous close.

A number of other research firms have also recently weighed in on ONCE. UBS AG reaffirmed a “buy” rating and issued a $92.00 price target (up previously from $70.00) on shares of Spark Therapeutics in a report on Thursday, August 3rd. BMO Capital Markets reaffirmed an “outperform” rating and issued a $89.00 price target (up previously from $69.00) on shares of Spark Therapeutics in a report on Thursday, August 3rd. Chardan Capital raised Spark Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the stock from $60.00 to $100.00 in a report on Tuesday, August 8th. Zacks Investment Research cut Spark Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $92.00 target price (up previously from $77.00) on shares of Spark Therapeutics in a report on Thursday, August 3rd. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and twelve have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $82.32.

Spark Therapeutics (ONCE) traded down 1.6787% during mid-day trading on Wednesday, hitting $77.6345. The company had a trading volume of 70,372 shares. The company has a 50-day moving average price of $68.68 and a 200 day moving average price of $60.30. The firm’s market capitalization is $2.43 billion. Spark Therapeutics has a 12 month low of $35.07 and a 12 month high of $80.89.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.75) by $0.14. The business had revenue of $1.48 million during the quarter, compared to analyst estimates of $1.33 million. Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. The business’s revenue for the quarter was up 14.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.04) EPS. Equities analysts forecast that Spark Therapeutics will post ($7.57) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This article was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was stolen and reposted in violation of United States and international trademark and copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/08/16/spark-therapeutics-inc-once-research-coverage-started-at-evercore-isi.html.

In other news, CFO Stephen W. Webster sold 7,663 shares of the company’s stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $60.00, for a total value of $459,780.00. Following the completion of the sale, the chief financial officer now directly owns 10,163 shares in the company, valued at $609,780. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Stephen W. Webster sold 2,337 shares of the company’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $71.12, for a total value of $166,207.44. Following the completion of the sale, the chief financial officer now owns 4,837 shares of the company’s stock, valued at $344,007.44. The disclosure for this sale can be found here. Insiders sold 339,310 shares of company stock valued at $23,787,138 over the last 90 days. Company insiders own 7.30% of the company’s stock.

Several large investors have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. raised its stake in Spark Therapeutics by 23.6% in the second quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock worth $122,000 after buying an additional 389 shares during the period. Cubist Systematic Strategies LLC bought a new stake in Spark Therapeutics during the second quarter worth about $143,000. BNP Paribas Arbitrage SA raised its stake in Spark Therapeutics by 530.1% in the second quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock worth $174,000 after buying an additional 2,449 shares during the period. Pacad Investment Ltd. raised its stake in Spark Therapeutics by 75.0% in the second quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock worth $209,000 after buying an additional 1,500 shares during the period. Finally, Highbridge Capital Management LLC acquired a new position in shares of Spark Therapeutics during the first quarter valued at $227,000. Institutional investors and hedge funds own 87.30% of the company’s stock.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.